Recipharm Presents its Sixth Internatio?nal Environmen?tal Award winner
Recipharm AB is proud to announce that its sixth International Environmental Award has been awarded to Ludwig Metz, Associate Director Environmental, Health & Safety, at pharmaceutical company Bristol–Myers Squibb.
The purpose of the the Recipharm International Environmental Award is to encourage and inspire best practice and innovation to promote good examples and to encourage environmental dialog within the pharmaceutical industry.
The prize is awarded annually by Recipharm to the best environmental performance or environmental best practice and innovation by the pharmaceutical industry or the academic community. Since Recipharm was founded in 1995, its commitment to environmental best practice has been a pivotal corporate mission.
Lars Backsell, Chairman of Recipharm, commented: “Ludwig Metz’s longstanding work is an excellent example of how sustainability activities and competence within a private business-focused organisation can inspire and be shared and used throughout society. Ludwig Metz has not only inspired his own company, but also universities, pharmacies and organisations to make positive changes to improve their ways of working with respect to sustainability. Through his ability to turn vision into reality, and through his support to industry stakeholders, he is a role model within the pharmaceutical industry.”
Commenting on winning the award, Ludwig Metz remarked; “The award makes me very proud and is a great honor to receive, especially considering its international and unique characteristics. To my knowledge this is the first time that an “innovative practitioner” has been selected. This Award provides recognition for my work and engagement during the past 20 years to promote effective Sustainability supported by my company, Bristol-Myers Squibb. The Recipharm Environmental Award is an encouragement for me and other professionals to continue developing and sharing innovative programmes to successfully integrate Sustainability and motivate others to participate.”
For the past 26 years, Ludwig Metz has been working in the field of Environment, Health, Safety and Sustainability for the pharmaceutical company Bristol-Myers. He is Associate Director and his play field is Europe. He started his International work in 1996 when he moved to the global acting Corporate Environment, Health, Safety and Sustainability department. Metz has established a complete network of partners in Europe, such as experts at universities, associations and rating companies. He has also supported the development of the sustainable goals and activities of various organisations and universities.
Previous laureates:
2012 Dr Damià Barceló, Director of the Catalan Institute for Water research (ICRA) in Spain
2011 Professor Benoit Roig, École des Hautes Études en Santé Publique, France
2010 Wellcome Trust Sanger Institute, Hinxton, Cambrigde, UK
2009 Professor Klaus Kümmerer, Freiburg University, Germany
2008 Apoteket AB, Sweden
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance